Our Research Grants

CureSHANK has dedicated more than $400,000 toward funding research grants in 2023-2024. These grants address some of the highest priority deficits in the translational research gap between basic SHANK3 science and successful clinical trials for individuals living with Phelan-McDermid syndrome (PMS). With continued financial support from our donors, CureSHANK plans to continue and increase our funding of these types of urgently needed research projects.

See our Funding Opportunities page for researchers for other sources of research grants.

A female doctor holding a piggy bank

The CURESHANK Research-to-cure grant: EPILEPSY ($250,000 total)

"Assessing the contribution of GABAergic neuron hypofunction to pathological network states in Phelan-McDermid Syndrome (PMS)"

Jordan S. Farrell, PhD
Boston Children's Hospital

Summary: Loss of the Shank3 gene in PMS disrupts brain activity in people with the condition, sometimes as seizures and often as subtler abnormal communication patterns between nerve cells. We think this is because Shank3 loss impairs the brain’s “brake” cells (GABAergic neurons) that keep neural activity in check. In mice, we will test whether losing Shank3 produces these abnormal brain rhythms and whether removing it only from the “brake” cells is enough to trigger seizures. The results will help to learn more about the underlying cellular mechanisms of PMS, assisting researchers to design more targeted therapies.

"Inhibitory circuits underlying epileptogenesis in Shank3-deficiency”

Nick Frost, MD/PhD
University of Utah

Summary: People with PMS-SHANK3 gene disruptions often have social difficulties, intellectual disability, and epilepsy, but it’s unclear how the SHANK3 disruptions leads to seizures. Our earlier work in mice showed overactive brain cells in the forebrain linked to faulty inhibitory “brake”. We now propose to build the first seizure-induction (kindling) model in Shank3-deficient mice to test whether these “brake” cells let activity spread too easily between brain regions important for cognition. The findings will pinpoint specific cell types that future therapies could target to normalize brain activity and reduce seizure risk.

The CURESHANK Research-to-cure grant: Developmental regression ($125,000 total)

Developmental regression is one of the most heartbreaking symptoms of Phelan-McDermid syndrome (PMS). Nearly all parents of children with PMS have watched helplessly as their child loses skills once mastered. Sometimes this happens gradually and sometimes abruptly; for some it seems triggered by a specific health event, while for others there is no discernible catalyst. It usually happens to younger children, but it can happen anytime during childhood. Occasionally, skills are almost fully restored, but much more commonly, many are never recovered.

research grant Co-Sponsorships
$40,000 to date


Autism Science Foundation logo

Autism Science Foundation

CureSHANK is helping sponsor two Autism Science Foundation (ASF) Profound Autism Pilot Grants. Most individuals with Phelan-McDermid syndrome are diagnosed with autism and are usually categorized as requiring very substantial support (“Level 3”). Research involving individuals with profound autism is therefore often of high interest to CureSHANK and to the PMS community.


Candid

CANDID (Consortium for Autism, Neurodevelopmental Disorders & DIgestive Diseases) is a multidisciplinary collaboration between patient advocacy groups, scientists, clinician, and research organizations that is focused on addressing the common occurrence of gastrointestinal dysfunction in individuals with neurodevelopmental disorders. PMS is no exception: GI issues are cited as a significant challenge by many caregivers of individuals with PMS.